Cavalier Jason 4

What Happened

• Jason Cavalier, Principal Financial Officer (CFO) of Lyra Therapeutics (LYRA), reported a disposition to the issuer of 667 shares on 2026-04-01. The reported price per share was $0.00, for total cash proceeds of $0.00. The Form 4 was filed on 2026-04-03 (Accession: 0001193125-26-142099).

Key Details

• Transaction type/code: Disposition to the issuer (D).
• Transaction date: 2026-04-01; Form 4 filed: 2026-04-03.
• Price: $0.00 per share; Total proceeds: $0.
• Shares disposed: 667.
• Shares owned after transaction: not specified in the provided filing details.
• Filing timeliness: filed two days after the transaction (appears timely based on filing date).
• Accession number: 0001193125-26-142099.

Context

• "Disposition to the issuer" often reflects shares surrendered back to the company (commonly for tax withholding, share cancellation, or net settlement) but the Form 4 entry does not state the reason. Because there were no cash proceeds, this is not an open-market sale and does not directly signal buying or selling sentiment. For retail investors, outright purchases typically carry more direct informational weight than internal share surrenders.